168 related articles for article (PubMed ID: 29349077)
1. The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma.
Wan X; Liu R; Li Z
Biomed Res Int; 2017; 2017():5356737. PubMed ID: 29349077
[TBL] [Abstract][Full Text] [Related]
2. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
3. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
5. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
[TBL] [Abstract][Full Text] [Related]
7. NRAS mutant melanoma--undrugable?
Posch C; Ortiz-Urda S
Oncotarget; 2013 Apr; 4(4):494-5. PubMed ID: 23660168
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
10. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
11. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
12. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao H; Zhang X; Fowlkes K; Haluska FG
Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
[TBL] [Abstract][Full Text] [Related]
13. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
14. Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma.
Fan Y; Liang X; Yu D
Aging (Albany NY); 2021 Oct; 13(19):23036-23071. PubMed ID: 34613934
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
16. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
Weyandt J
Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
[TBL] [Abstract][Full Text] [Related]
17. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of NRAS isoforms in Chinese melanoma patients.
Yan J; Xu L; Yu J; Wu X; Dai J; Xu T; Yu H; Guo J; Kong Y
Melanoma Res; 2019 Jun; 29(3):263-269. PubMed ID: 30489482
[TBL] [Abstract][Full Text] [Related]
19. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
Guo H; Cheng Y; Martinka M; McElwee K
Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
Wu ZS; Cheng XW; Wang XN; Song NJ
Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
